NeuroMetrix, Inc. (NASDAQ:NURO) Short Interest Update

NeuroMetrix, Inc. (NASDAQ:NURO) saw a large growth in short interest in the month of July. As of July 31st, there was short interest totalling 29,700 shares, a growth of 45.6% from the July 15th total of 20,400 shares. Based on an average daily trading volume, of 12,600 shares, the days-to-cover ratio is presently 2.4 days. Currently, 1.9% of the shares of the company are short sold.

NeuroMetrix Trading Up 14.6 %

Shares of NURO traded up $0.42 during mid-day trading on Wednesday, hitting $3.29. The company’s stock had a trading volume of 35,028 shares, compared to its average volume of 28,757. NeuroMetrix has a 1-year low of $2.66 and a 1-year high of $6.99. The firm has a market capitalization of $6.62 million, a P/E ratio of -0.54 and a beta of 2.30. The firm has a 50-day simple moving average of $3.61 and a 200 day simple moving average of $3.76.

NeuroMetrix (NASDAQ:NURO) last released its quarterly earnings data on Wednesday, May 15th. The medical device company reported ($1.67) earnings per share (EPS) for the quarter. The business had revenue of $1.09 million during the quarter. NeuroMetrix had a negative return on equity of 39.85% and a negative net margin of 151.51%.

Analyst Upgrades and Downgrades

Separately, StockNews.com assumed coverage on shares of NeuroMetrix in a research report on Thursday, August 8th. They issued a “sell” rating for the company.

Hedge Funds Weigh In On NeuroMetrix

A hedge fund recently bought a new stake in NeuroMetrix stock. Cerity Partners LLC acquired a new position in shares of NeuroMetrix, Inc. (NASDAQ:NURO) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 30,000 shares of the medical device company’s stock, valued at approximately $108,000. Cerity Partners LLC owned approximately 2.80% of NeuroMetrix at the end of the most recent quarter. 19.40% of the stock is currently owned by institutional investors and hedge funds.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.